Allos Therapeutics to Present at BIO CEO & Investor Conference
February 03 2010 - 7:00AM
Business Wire
Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical
company committed to the development and commercialization of
innovative anti-cancer therapeutics, today announced that members
of the Company’s senior management will present on Monday, February
8, at 2:30 p.m. EST at the 12th Annual BIO CEO & Investor
Conference taking place at the Waldorf-Astoria Hotel in New York
City.
There will be a live webcast of the presentation, which will be
accessible through a link available on the home page and investor
relations section of the Allos website.
About Allos Therapeutics
Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical
company committed to the development and commercialization of
innovative anti-cancer therapeutics. Allos is currently focused on
the development and commercialization of FOLOTYNTM (pralatrexate
injection), a folate analogue metabolic inhibitor. FOLOTYN is the
first and only drug approved in the U.S. for the treatment of
patients with relapsed or refractory peripheral T-cell lymphoma.
Allos is also exploring the potential of FOLOTYN in other
indications. Allos retains exclusive worldwide rights to FOLOTYN
for all indications. Allos is headquartered in Westminster, CO. For
additional information, please visit www.allos.com.
Safe Harbor Statement
The anticipated presentation will contain forward-looking
statements that involve significant risks and uncertainties.
Additional information concerning these forward-looking statements
and other factors that may cause actual results to differ
materially from those anticipated in the forward-looking statements
is contained in the "Risk Factors" section of the Company's
Quarterly Report on Form 10-Q for the quarter ended September 30,
2009 and in the Company's other periodic reports and filings with
the Securities and Exchange Commission. The Company cautions
investors not to place undue reliance on the forward-looking
statements contained in the presentation. All forward-looking
statements are based on information currently available to the
Company on the date thereof, and the Company undertakes no
obligation to revise or update these forward-looking statements to
reflect events or circumstances after the date of these
presentations, except as required by law.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Allos Therapeutics, Inc. (MM) (NASDAQ): 0 recent articles
More Allos Therapeutics, Inc. News Articles